Once-Weekly Oral Islatravir Plus Lenacapavir Versus Daily Oral Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Persons With HIV-1 : A Phase 2 Randomized Study.

Overview of attention for article published in Annals of Internal Medicine, December 2025

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (97th percentile)
High Attention Score compared to outputs of the same age and source (80th percentile)

Mentioned by

news: 5 news outlets
twitter: 9 X users
facebook: 1 Facebook page

reddit: 1 Redditor
bluesky: 5 Bluesky users
podcasts: 1 podcast

Readers on

mendeley: 10 Mendeley

So far, Altmetric has seen 9 X posts from 9 X users, with an upper bound of 65,041 followers.

RT @ABsteward: 🆕⚡Phase 2 Randomized Study Once-Weekly Oral Islatravir Plus Lenacapavir Versus Daily Oral Bictegravir, Emtricitabine, and Te…

●HIV陽性者への週1回経口投与イスラトラビル/レナカパビル(ISL/LEN)vsB/F/TAF　第2相RCT Ann Intern Med ・HIV-RNA50コピー未満,B/F/TAF24w投与が対象・ 24wでISL+LEN群1 名でHIV-RNA50コピー以上だが、B/F/TAF群で0名 (95%CI-5.2-10.5%)。48wで50コピー/mL以上はおらず。 h…

RT @ABsteward: 🆕⚡Phase 2 Randomized Study Once-Weekly Oral Islatravir Plus Lenacapavir Versus Daily Oral Bictegravir, Emtricitabine, and Te…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 5 additional X posts.